FDA Approves Telix’s Prostate Cancer Imaging Product, Illuccix®
Go back to FDA Approves Telix’s Prostate Cancer Imaging Product, Illuccix®| TRANS-LUX CORPORATION (NASDAQ: TLX) | Delayed: 11.33 -1.09 (8.78%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $12.42 | 52 Week High | $2.18 | |||
| Open | $11.34 | 52 Week Low | $0.30 | |||
| Day High | $11.39 | P/E | N/A | |||
| Day Low | $11.19 | EPS | $-3.32 | |||
| Volume | 299,627 | |||||
